NRAS G13D

CI-VAR-00001632Explore in graph →NP_002515.1:p.Gly13AspNM_002524.4:c.38G>AClinVar 13901 CIViC 93 rs121434596

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Colorectal Neoplasm1
NRAS G13D	Cetuximab	Predictive	D	Supports Resistance	—	submitted	EID3840 In an in vitro study, an OXCO-2 cell line expressing NRAS G13D mutation demonstrated acquired resistance after low level cetuximab exposure compared to OXCO-2 parental cells expressing NRAS wild-type.… (full text at CIViC) PMID 24553387 · Misale et al., 2014 · Open in CIViC	civic
Melanoma1
NRAS G13D	Tanespimycin	Predictive	C	Supports Sensitivity Response	2	accepted	EID21 Likely due to increased reliance of mutant NRAS on HSP90 for stabilization, inhibition of HSP90 by 17-AAG was shown to be effective in a patient with metastatic malignant melanoma with an NRAS G13D mu… (full text at CIViC) PMID 18375819 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.